TC Biopharm (Holdings) Plc Price & Performance (TCBPW)

TC BioPharm (TCBP) will be removed from the Nasdaq and begin trading on the OTC Markets following its inability to meet the exchange’s $1 minimum bid price requirement. Management is appealing the decision, but the transition is effective March 24. The company will maintain its SEC reporting obligations and continue clinical operations.123

TC BioPharm is restructuring, shifting to a contract development model and reducing staff by about 50%, aiming for annual savings of $4.2 million. The company also signed a non-binding letter to acquire an ophthalmic pharma firm, targeting revenue growth and diversification. These moves mark a significant pivot in its business strategy.43

TC BioPharm’s stock remains highly volatile, trading at $0.50 with no recent price change but signaling risk and unpredictability. Technical indicators offer mixed signals, and analysts suggest holding rather than buying, as the stock’s direction remains unclear given ongoing operational and financial challenges.56